The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarillion Plc Regulatory News (CLLN)

  • This share is currently suspended. It was suspended at a price of 14.27

Share Price Information for Carillion Plc (CLLN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.27
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.27
CLLN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal

31 Oct 2017 07:00

RNS Number : 0643V
Carillion PLC
31 October 2017
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE

31 October 2017

 

Carillion plc ("Carillion" or the "Group")

£13.8 million disposal of interests in Ask Real Estate

 

The Board of Carillion today announces the disposal of the Group's:

 

(i) 66.67% shareholding in Ask Real Estate Limited ("AREL"), and a shareholder loan made by Carillion Construction Limited to AREL's subsidiary, Ask Central Limited; and

(ii) 50% interest in Ask Carillion Developments LLP ("ACD"),

 

to one or more wholly owned subsidiaries of Dukehill Limited ("Dukehill"), for aggregate cash consideration of £13,800,000 (the "Transaction"). £1,000,000 of the cash consideration is contingent on the sale of 100 Embankment and will be paid by Dukehill within 5 business days of signing of the sale documentation in relation to this.

 

AREL and ACD (through their wholly owned subsidiaries and other associated entities) carry out commercial property development activities, together with various partners, in the North of the UK, including Manchester, Liverpool and Leeds.

 

For the 2016 Financial Year, the interests that are the subject of the Transaction contributed £4.1 million of revenue, £11.6 million profit before tax, and £19.2 million gross assets as at 31 December 2016. The contribution to profit from Carillion's interests in AREL and ACD can vary significantly from year to year. The transaction is expected to generate a modest profit on disposal, and the interests being sold were not expected to make a material contribution to overall Group profit for 2017.

 

The transaction consideration will be applied in reducing the Group's overall leverage position and, following the Transaction, AREL will be deconsolidated from the Group's accounts. AREL managing director, John Hughes and finance director, Jonathan Cross, who together own 33.33% of AREL, will retain their executive positions.

 

Commenting, Keith Cochrane, Interim Chief Executive, said:

'We are pleased to be able to announce further progress. Much remains to be done, and we are continuing to execute our plans to refocus the business, reduce cost and strengthen our balance sheet.'

 

The person responsible for the release of this announcement on behalf of Carillion plc is Westley Maffei.

Enquiries:

Investors/ Analysts:

Carillion plc

Kellie McAvoy, Head of Investor Relations +44 (0) 1902 906333

John Denning, Director Group Corporate Affairs

 

 

Media:

Teneo Blue Rubicon +44 (0) 207 420 3197

Charles Armitstead / Haya Herbert-Burns

 

This and other Carillion news releases can be found at www.carillion.plc 

Cautionary statement

This announcement may contain indications of likely future developments and other forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. These and other factors could adversely affect the Group's results, strategy and prospects. Forward-looking statements involve risks, uncertainties and assumptions. They relate to events and/or depend on circumstances in the future which could cause actual results and outcomes to differ materially from those currently anticipated. No obligation is assumed to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISUAVNRBAARORA
Date   Source Headline
3rd Apr 20187:30 amRNSUpdate re Liquidation of Carillion
19th Mar 20187:00 amRNSFRC investigation
17th Jan 20188:15 amRNSAnnouncement Re. Carillion PLC
15th Jan 20187:45 amRNSSuspension - Carillion PLC
15th Jan 20187:00 amRNSCompulsory liquidation of Carillion
12th Jan 20186:08 pmRNSUpdate on discussions with creditors
12th Jan 20185:08 pmRNSHolding(s) in Company
10th Jan 20185:48 pmRNSHolding(s) in Company
9th Jan 20187:03 amRNSResponse to share price movement
3rd Jan 20184:44 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSRegulatory investigation
22nd Dec 20177:00 amRNSUpdate on financial covenant deferral
20th Dec 201710:16 amRNSBlock listing Interim Review
20th Dec 20177:00 amRNSChief Executive Appointment
13th Dec 20177:00 amRNSUpdate on UK healthcare facilities business
11th Dec 20177:58 amRNSHolding(s) in Company
1st Dec 20177:00 amRNSDirectorate Change
23rd Nov 201712:08 pmRNSHolding(s) in Company
22nd Nov 201712:29 pmRNSHolding(s) in Company
21st Nov 20174:11 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFramework Award
17th Nov 20177:02 amRNSUpdate
15th Nov 20177:00 amRNSOman - letter of award for contract
6th Nov 20177:00 amRNSContract wins
2nd Nov 20177:00 amRNSDirectorate Change
31st Oct 20177:00 amRNSDisposal
27th Oct 20177:00 amRNSChief Executive Appointment
24th Oct 20177:00 amRNSUpdate on financing, disposals and work winning
12th Oct 201712:43 pmRNSUK Healthcare business
4th Oct 20172:58 pmRNSHolding(s) in Company
29th Sep 20177:00 amRNSHalf-year Report
22nd Sep 20171:00 pmRNSHolding(s) in Company
19th Sep 20174:55 pmRNSHolding(s) in Company
11th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:17 pmRNSAnnouncement of 2017 interim results
17th Aug 20174:19 pmRNSHolding(s) in Company
15th Aug 20175:58 pmRNSHolding(s) in Company
11th Aug 20176:20 pmRNSHolding(s) in Company
8th Aug 20173:59 pmRNSHolding(s) in Company
8th Aug 201710:02 amRNSHolding(s) in Company
3rd Aug 20179:02 amRNSHolding(s) in Company
1st Aug 201712:24 pmRNSHolding(s) in Company
31st Jul 20172:57 pmRNSHolding(s) in Company
27th Jul 20176:28 pmRNSHolding(s) in Company
18th Jul 201710:49 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSCarillion JV awarded two further HESTIA contracts
17th Jul 20177:19 amRNSHS2 Contract Award
17th Jul 20177:00 amRNSCarillion appoints EY to support strategic review
14th Jul 201712:20 pmRNSHolding(s) in Company
14th Jul 20177:00 amRNSAppointment of Joint Financial Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.